Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Unite Acquisition 1
Charlotte, North Carolina, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Unite Acquisition 1 dissolved into Adaptin Bio via merger; Adaptin preparing first-in-human Phase 1 trial for APTN-101, an EGFRvIII-targeting BRiTE therapeutic for glioblastoma. Preclinical studies show >7-fold improved distribution in brain; FDA IND clearance for first human trial.
- Therapeutic areas
- OncologyRare Diseases
- Modalities
- Bispecific monoclonal antibodyBispecific T cell engager
- Industry
- Biotech
02
Partnerships
Collaboration with Duke UniversityLaidlaw & Company (UK) Ltd.
Beyond the preview
Go deeper on Unite Acquisition 1.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Unite Acquisition 1.